The Fenofibrate And Microvascular Events in Type 1 diabetes Eye (FAME 1 Eye): A randomised trial to evaluate the efficacy on retinopathy and safety of fenofibrate in adults with type 1 diabetes. A multicentre double-blind placebo-controlled study in Australia and internationally

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 10 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fenofibrate (Primary)
Indications Diabetic macular oedema; Diabetic retinopathy
Focus Therapeutic Use
Acronyms FAME-1-EYE

Most Recent Events

21 Dec 2022 Planned End Date changed from 1 Jan 2025 to 1 Dec 2025.
21 Dec 2022 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2024.
22 Nov 2021 Accrual to date is 203 participants as per Australian New Zealand Clinical Trials Registry record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight